Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

Fig. 4

Responses to HIT-6 item 1 (severe pain) in eptinezumab-treated patients maintaining ≥ 75% migraine response over Weeks 1–12 in PROMISE-2 at (A) baseline and (B) Week 12 and those maintaining ≥ 50–< 75% migraine response over Weeks 1–12 in PROMISE-2 at (C) baseline and (D) Week 12. Item 1 of the 6-item Headache Impact Test (HIT-6) asked “When you have headaches, how often is the pain severe?” A ≥ 75% or ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 75% or ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. Epti, eptinezumab

Back to article page